Revalesio’s Charge-Stabilized Nanostructure Technology is based on a patented modification of Taylor-Couette-Poiseuille (TCP) flow. TCP flow combines intense local turbulence, providing large energy dissipation rates and surface-to-volume mixing ratios. Specific process conditions generate a strong shear layer at the interface between the vapor and liquid phases correlating with the generation of nanobubbles from cavitation. Fluids produced in this manner have shown robust effects in multiple biological systems.
Modified TCP flow was initially explored for hydrogen gas production. Although this goal was never achieved, exploratory research in other areas revealed promising effects. Revalesio acquired the technology and shifted the focus of research to biological systems.
Research & Development
Revalesio is developing RNS60, a novel therapeutic that has the potential to treat a variety of neurological diseases. Based on an extensive pre-clinical research program, RNS60 has entered clinical evaluation in the US and Europe. After demonstrating its excellent tolerability in Phase I safety studies, RNS60 is now being tested in Phase 2 studies in patients with multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS).